PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
– PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial – – Confirmatory trial found…